Results
- Patients completed pre-screen
- 82
- Patients completed screening at an active site
- 46
- Patients randomized in 12 months (~30% of trial)
- 22
Situation
A biopharmaceutical company developing innovative therapies for people with rare debilitating diseases sought to accelerate trial enrollment.
Approach
- Designed and implemented a compliant patient lead generation program targeting full enrollment
- Directed patients to a clinical trial website with a digital prescreener
- Gave authorized clinical trial personnel secure access to patient screening and enrollment data via the Adnexi Portal
More case studies
All case studies-
14
participants enrolled through advocacy outreach, 18% of
trial enrollmentRare oncology
17 patient advocacy DOLs engaged144 discussion guides downloaded95 prescreeners in 7 months
-
24
patients randomized in 9 months in a program supporting 50
US and Canadian sitesPhase 2, neurodegenerative disease
Prescreened 250Screened 52Randomized 24